Topic

Articles

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.

Biopharma M&A: Year in Review, Ripples Ahead

Is stock market outperformance for biotech still in the cards for 2023?

More than Ever, Data Will Dictate Future Fortunes 

Kyle Forcier is the senior director of life sciences and product marketing for Model N.

According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions. 

An Inside Look at Pharma Revenue Management

Chronicling the market’s rise and fall—and signs of potential recovery.

Data Signals Some Green Shoots for Biotech in 2023 

What a changing economy and related trends could mean for 2023.

Biopharma Investment Implications: Looking Back and Forward 

Will biopharma investment heat up and signal better fortunes for 2023? 

Back in Person, Sparks Could Fly at Upcoming J.P. Morgan Conference

Focus is on cash: who’s got it, who doesn’t, and what will it mean?

The New Reality for Industry Dealmaking May be Setting In

William Borden is a freelance journalist covering the pharmaceutical industry. He is based in New Jersey.

Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.

Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A Race

As fundamentals improve, potential rate plateau could ignite growth.

All About the Rates: The Fallout of Fed Hikes for Biotech

Rotz discusses a report he co-authored for PwC about how life sciences companies perform on the S&P 500.

Finance